<DOC>
	<DOCNO>NCT00403520</DOCNO>
	<brief_summary>The purpose study demonstrate donepezil slow progression Alzheimer 's disease ( AD ) use magnetic resonance imaging ( MRI ) brain measure volume hippocampus patient pre-dementia Alzheimer 's disease .</brief_summary>
	<brief_title>Hippocampus Study : Comparative Effect Donepezil 10mg/d Placebo Clinical Radiological Markers</brief_title>
	<detailed_description>The development new automate method measurement volume hippocampus allow confirm result patient present pre-dementia Alzheimer 's Disease ( AD ) , treat donepezil order verify product capable stop speed atrophy hippocampus patient specifically evolve AD , compare placebo . This method semi automatic segmentation hippocampus MRI , make competitive region grow . It develop cognitive neuroscience MRI laboratory Pitié-Salpêtrière hospital . This method validate healthy subject Alzheimer 's disease patient comparison manual segmentation . Neuropsychological test realize order supervise clinical evolution patient correlate result progression atrophy hippocampus .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion Criteria ( Baseline Visit ( `` V0 '' ) : 1.Men Women 50 year old . 2 . Patients mild cognitive impairment ( MCI ) progressive hippocampal amnestic syndrome , isolate associated cognitive disorder define Free cue selective reminding test ( FCSRT ) Free Recall &lt; = 17 OR Total Recall &lt; 40 , accord Grober Buschke procedure , modify accord result PREAL study 3.Clinical Dementia Rating ( CDR ) = 0.5 4 . General cognition functional performance sufficiently preserve diagnosis Possible Probable Alzheimer 's Disease base Diagnostic Statistical Manual Mental Disorders DSMIV criterion ) make site physician time screen visit . This evidence must fully document subject 's study file Randomization visit . 5 . Outpatient informant person : person his/her close circle regular weekly contact patient accept answer assessment questionnaire . 6 . Visual , hear capacity ( authorized equipment ) oral write expression , sufficient correct performance test ( accord physician 's opinion ) . 7 . Patient informant person sign write informed consent form . Exclusion Criteria ( Baseline Visit ( `` V0 '' ) : 1 . Patients contraindication MRI : Pacemaker , cardiac defibrillator neurostimulator wearer Wearers implant material activate electric , magnetic mechanical system Wearers haemostatic clip intracerebral aneurysm carotid artery Wearers cochlear implant Patients intraocular metallic foreign body Claustrophobic patient Any contraindication MRI 2 . Patients evolutive psychiatric pathology and/or unstable accord DSMIV , particularly : Major depressive episode previous 2 year recurrent depression bipolar disorder accord DSMIV and/or score &gt; = 12 accord 17items depressive Hamilton 's Scale Patients present early hallucination cognitive fluctuation 3 . Patients neurological disorder : Partial complex epilepsy Dementia origin Patients Parkinson 's disease 4 . Any patient history intercurrent lesion find brain imaging study . 5 . Patient present major repercussion autonomy , assess Instrumental Activities Daily Living ( IADL ) Lawton score high equal 2 least 2 item high 2 least 1 item , confirm informant person . 6 . Patient le 14 word identification phase FCSRT ( Free Cued Selective Reminding Test ) 7 . Known vitamin B12 folates deficiency ( except replacement treatment stable posology since least 6 month selection ) know syphilis . 8 . Abnormal Thyroid function ( T3 , T4 , ultrasensitive thyroid stimulate hormone ( TSH ) . Euthyroid patient treat stable dos least 3 month could include . 9 . Insulin dependent diabetes diabetes control regimen and/or oral antidiabetic , obstructive pulmonary disease , unstable asthma , recent hematological and/or oncological disorder ( 2 year ) . 10 . Gastrointestinal , renal , hepatic , endocrine cardiovascular clinically significant disease . Atrioventricular block 2nd 3rd degree ECG . 11 . Patient bradycardia &lt; = 50 beat per minute . 12 . Patient unstable hypertension ( systolic blood pressure &gt; 160 mmHg /or diastolic blood pressure &gt; 95 mmHg ) assess investigator , patient treat antihypertensive drug . 13 . Patient previously treat central cholinesterase inhibitor memantine whatever duration treatment date prescription 14 . Patient treat nonauthorized drug study 15 . Known suspected history ( 5 year ) alcoholism , abusive drug use . 16 . Patients know hypersensitivity donepezil chlorhydrate , piperidine derivative one excipients drug . 17 . Patients participate clinical trial previous 3 month . Inclusion criterion ( Visit 1 ) : 1 . Patients mild cognitive impairment ( MCI ) progressive hippocampal amnestic syndrome , isolate associated cognitive disorder 2 . General cognition functional performance sufficiently preserve diagnosis Possible Probable Alzheimer 's Disease base clinical neuroimaging finding ( NINCDSADRDA DSMIV criterion ) make site physician time screen visit . This evidence must fully document subject 's study file . 3 . Outpatient informant person : person his/her close circle regular weekly contact patient accept answer assessment questionnaires 4 . Patients perform electrocardiogram ( ECG ) within previous 6 month 5 . Visual , hear capacity ( authorized equipment ) oral write expression , sufficient correct performance test ( accord physician 's opinion ) 6 . Clinical laboratory value must within normal limit , abnormal , judge clinically insignificant investigator ( likely cause cognitive impairment medical instability ) 7 . Clinical Dementia Rating ( CDR sum box ) = 0.5 Exclusion criterion ( Visit 1 ) : 1 . Patients evolutive psychiatric pathology and/or unstable accord DSMIV , particularly : Major depressive episode ongoing recurrent depression bipolar disorder accord DSMIV and/or score &gt; = 12 accord 17items depressive Hamilton 's Scale Patients present early hallucination cognitive fluctuation 2 . Any patient presenting intercurrent lesion MRI perform screen must exclude study , apart minor nonprogressive lesion alter brain morphology 3 . Patients neurological disorder : Partial complex epilepsy Dementia origin Patients Parkinson 's disease 4 . Patient One MRI Exclusion criterion : Stroke sequelae More one ischemic lacuna Age relate white matter change Flair image &gt; Fazekas Schmidt grade 2 Active ischemic lesion Diffusion weight Images ( DWI ) 5 . Patient present major repercussion autonomy , assess IADL Lawton score high equal 2 least 2 item high 2 least 1 item , confirm informant person . 6 . Known vitamin B12 folates deficiency ( except replacement treatment stable posology since least 6 month selection ) know syphilis . 7 . Abnormal Thyroid function ( T3 , T4 , free thyroxine index , TSH ) . Euthyroid patient treat stable dos least 3 month could include . 8 . Insulin dependent diabetes diabetes control regimen and/or oral antidiabetic , obstructive pulmonary disease , unstable asthma , recent hematological and/or oncological disorder ( &lt; = 2 year ) . 9 . Gastrointestinal , renal , hepatic , endocrine cardiovascular clinically significant disease . Atrioventricular block 2nd 3rd degree ECG . 10 . Patients bradycardia &lt; = 50 . 11 . Patients unstable hypertension ( systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 95mmHg ) assess investigator , patient treat anti hypertensive drug . 12 . Patient previously treat central cholinesterase inhibitor memantine whatever duration treatment date prescription 13 . Patient treat nonauthorized drug study 14 . Known suspected history ( &lt; = 5 year ) alcoholism , abusive drug use . 15 . Patients know hypersensitivity donepezil chlorhydrate , piperidine derivative one excipients drug . 16 . Patients participate clinical trial previous 3 month . 17 . Patient treat nonauthorized drug study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Mild cognitive impairment</keyword>
</DOC>